Neurochemical ResearchNov 2, 2026, 09:24 GMT

Hinokitiol reduced toxin damage in lab-grown cells

Experiments in a lab-grown nerve-cell model found less toxicity from rotenone after pretreatment with hinokitiol at 25 and 50 micromolar.

Paper by Devadharuna Mohan, Choudary Soujanya, Raghul Venkatesan, +4Divakar Selvaraj · JSS Academy of Higher Education and Research

Figure 1 from Neurochemical Research — Figure 1. Mohan et al.

Our read

Interventions

Studied:: Experiments in retinoic acid-differentiated SH-SY5Y cells
What changed:: Pretreatment with 25 and 50 micromolar hinokitiol reduced toxicity from 10 micromolar rotenone
The catch:: GPX4 gene expression was measured, but direct GPX4 enzyme activation was not measured
In the record:: One of 3 papers on hinokitiol on record: 1 with results in people, 1 in animals.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper

Experiments in SH-SY5Y cells matured with retinoic acid tested whether hinokitiol protected this lab-grown nerve-cell model from rotenone, a toxin. Pretreatment with 25 and 50 micromolar hinokitiol reduced toxicity from 10 micromolar rotenone. It also reduced a marker of fat damage and iron levels inside cells, and increased activity of the gene for GPX4, an enzyme that limits such damage.

Computer simulations suggested stable hinokitiol binding to GPX4. In fruit flies, rotenone reduced mean survival to approximately 19 days. Adding hinokitiol extended it to about 23 days at 500 parts per million and 27 days at 1,000 parts per million. In mice with rotenone-induced Parkinson’s disease, hinokitiol reduced catalepsy, a state of rigid immobility, and improved movement and coordination. The authors suggested hinokitiol might limit nerve-cell degeneration, possibly by altering GPX4 activity.

Why it matters

The work explores whether ferroptosis—cell death driven by iron-dependent damage to fats—could be a target for protecting nerve cells in age-related Parkinson’s disease.

Caveats

These experiments used cells and animal models, not people with Parkinson’s disease. Simulated binding and increased gene activity do not establish that hinokitiol activated GPX4.